TCGA-BT-A0S7-01A-11R-A10U-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 6.570302234
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.510
- MYC_TARGETS_V1+0.490
- G2M_CHECKPOINT+0.470
- MYC_TARGETS_V2+0.400
- PROTEIN_SECRETION+0.340
- UNFOLDED_PROTEIN_RESPONSE+0.280
- MTORC1_SIGNALING+0.210
- SPERMATOGENESIS+0.150
- PANCREAS_BETA_CELLS+0.140
- ADIPOGENESIS+0.130
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.620
- INTERFERON_GAMMA_RESPONSE-0.490
- IL6_JAK_STAT3_SIGNALING-0.270
- INFLAMMATORY_RESPONSE-0.250
- APOPTOSIS-0.240
- IL2_STAT5_SIGNALING-0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.200
- XENOBIOTIC_METABOLISM-0.180
- ALLOGRAFT_REJECTION-0.170
- COMPLEMENT-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2956 | Med | Medulloblastoma | 0.845 |
| 2 | a7e776a3-4159-4cf7-8e05-2c2202330f58 | — | — | 0.843 |
| 3 | SRR10900595 | — | — | 0.842 |
| 4 | MNG1195 | — | — | 0.838 |
| 5 | TCGA-86-8054-01A-11R-2241-07 | — | cohortA3 | 0.836 |
| 6 | SRR25043616 | — | — | 0.834 |
| 7 | SRR33532819 | — | E | 0.826 |
| 8 | BS_MDBT7S5Z | high-grade glioma | — | 0.826 |
| 9 | TCGA-21-1072-01A-01R-0692-07 | — | cohortSQ2 | 0.824 |
| 10 | MNG1194 | — | — | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.090 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.060 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.050 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.030 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |